Perspectives for immunization of HLA-A1 patients carrying a malignant melanoma expressing gene MAGE-1.

Abstract

Many human melanoma tumors express antigens that are recognized in vitro by cytolytic T lymphocytes derived from the tumor-bearing patient. A gene has been identified that directs the expression of antigen MZ2-E on a human melanoma cell line. This gene, which has been named MAGE-1, shows no similarity to known sequences and belongs to a family of at least 3 closely related genes. Gene MAGE-1 is expressed in approximately 40% of melanoma tumor samples and by some tumors of other histological types. No expression has been observed in a panel of normal tissues. Antigen MZ2-E appears to be presented by HLA-A1, a HLA type found in approximately 25% of the population. Thus, precisely targeted experimental immunotherapy directed against antigen MZ2-E could be provided to individuals identified as HLA-A1 and MAGE-1 positive by HLA typing and analysis of the RNA of a small tumor sample.

• Authors: M Marchand, F Brasseur, P van der Bruggen, P Coulie, T Boon
• Journal: Dermatology (Basel, Switzerland) (Dermatology) Vol. 186 Issue 4 Pg. 278-80 ( 1993) ISSN: 1018-8665 [Print] Switzerland
• PMID: 8513199 (Publication Type: Journal Article)

Chemical References

• Antigens, Neoplasm
• HLA-A1 Antigen
• MAGEA1 protein, human
• Melanoma-Specific Antigens
• Neoplasm Proteins

Topics

• Antigens, Neoplasm (genetics, immunology)
• Gene Expression
• HLA-A1 Antigen (immunology)
• Humans
• Immunotherapy (methods)
• Melanoma (genetics, immunology, therapy)
• Melanoma-Specific Antigens
• Neoplasm Proteins
• T-Lymphocytes, Cytotoxic (immunology)
• Transfection